Natixis Advisors
WX

Natixis Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Natixis Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-9,622
Closed -$316K – 1293
2014
Q2 		$316K Sell
9,622
-9,365
-49% -$320K ﹤0.01% 1146
2014
Q1 		$700K Sell
18,987
-4,744
-20% -$174K 0.01% 864
2013
Q4 		$911K Buy
+23,731
New +$749K 0.01% 750

Other funds holding WX

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Natixis Advisors's WX Position: Q3 2014 in Review

Natixis Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q3 2014, closing a stake of 9,622 shares — an estimated $316K sold.

Natixis Advisors first reported a position in WX in Q4 2013 and held it in 3 quarters. The position peaked at $911K in Q4 2013. 157 funds tracked by Wall St. Rank hold WX as of Q3 2014.

  • Natixis Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q3 2014 after selling out during the quarter.
  • Natixis Advisors sold 9,622 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2014, an estimated $316K.
  • Natixis Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2013 and held it in 3 quarters.
  • Natixis Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $911K in Q4 2013.
  • 157 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2014.

Based on Natixis Advisors's 13F filing for Q3 2014, filed 3 Nov 2014.